Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 71288-118

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 71288-118). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Meitheal Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Bor02 0002 01 V2)

Chemical structure of Bortezomib, showing its molecular arrangement with nitrogen, oxygen, boron, and carbon atoms in a detailed 2D format.*

FDA Label Image

Figure 1 (Bor02 0002 02 V2)

A survival curve chart comparing the percentage of patients over time (in months) for two treatment groups labeled Vc-MP and MP. The chart shows a higher survival percentage for the Vc-MP group throughout the 24-month period, with time on the horizontal axis and percentage of patients on the vertical axis. A p-value from a log-rank test is indicated on the chart, suggesting statistical analysis of the difference between groups.*

FDA Label Image

Figure 2 (Bor02 0002 03 V2)

A line graph comparing the percentage of patients over time (months) between two groups, Vc-MP and MP. The y-axis represents the percentage of patients, and the x-axis represents time in months from 0 to about 78. Both lines show a decreasing trend, with Vc-MP consistently showing higher percentages than MP. A table below the graph shows the number of patients at risk for each group at various time points. A p-value of < 0.05 from a log-rank test is noted.*

FDA Label Image

Figure 3 (Bor02 0002 04 V2)

A Kaplan-Meier survival curve comparing the proportion of patients over time (days) treated with Bortezomib versus Dexamethasone. The graph shows higher patient survival proportion for Bortezomib throughout the study period. The x-axis represents time in days, and the y-axis shows the proportion of patients. A p-value from the log-rank test (<0.0001) is noted, indicating statistical significance.*

FDA Label Image

Figure 4 (Bor02 0002 05 V2)

A Kaplan-Meier survival curve chart showing the proportion of patients over time (up to 450 days) comparing Bortezomib and Dexamethasone treatments. The chart includes patient sample sizes at various timepoints and a p-value from a log-rank test indicating statistical significance.*

FDA Label Image

Figure 5 (Bor02 0002 06 V2)

A survival curve chart comparing two treatment groups, VcR-CAP and R-CHOP, over time in months up to 60 months. The vertical axis shows the percentage of patients, and the chart includes a log-rank test with a p-value <0.001. A table below the graph indicates the number of subjects at risk for each group at various time points.*

FDA Label Image

Figure 6 (Bor02 0002 07 V2)

A survival curve chart depicting the percentage of subjects alive over time in months from randomization for two treatment groups: VcR-CAP (solid line) and R-CHOP (dashed line). The chart includes a hazard ratio with 95% confidence interval (0.66, 0.51 to 0.85). Below the x-axis, the number of subjects at risk at various time points for each group is displayed.*

FDA Label Image

Principal Display Panel – Bortezomib For Injection 3.5 mg Vial Label (Bor02 0002 08 V3)

Bortezomib injection label for 3.5 mg per vial by Meitheal Pharmaceuticals Inc. The label indicates the product is a single-dose vial of lyophilized powder for intravenous or subcutaneous use. It includes storage instructions, dosage handling notes, and caution as a cytotoxic agent. The label also shows the NDC number 71288-118-10 and barcode.*

FDA Label Image

Principal Display Panel – Bortezomib For Injection 3.5 mg Carton (Bor02 0002 09 V3)

Packaging label for Bortezomib injection, powder, lyophilized, for solution, 3.5 mg per vial by Meitheal Pharmaceuticals Inc. The label indicates use for intravenous or subcutaneous injection, with reconstitution instructions for each method. The packaging also cautions that Bortezomib is a cytotoxic agent and includes storage and handling details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.